An experimental drug for early-stage dementia not only reduced the formulation of new beta amyloid clusters in the brain, a hallmark of Alzheimer's disease, it reduced existing clusters by 70% on average, American biotechnology company Biogen and Japanese drugmaker Eisai announced Wednesday.


원문출처 : https://www.cnn.com/2018/07/25/health/alzheimers-dementia-drug-ban2401-biogen-eisai-study/index.html